J Drugs Dermatol. 2021 Aug 1;20(8):837-843. doi: 10.36849/JDD.5845.
Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in patients who are eligible for phototherapy or systemic therapy. The drug increases cyclic adenosine monophosphate, cAMP, modulating the expression of pro-inflammatory cytokines. This review aims to explore and categorize current literature describing the efficacy and safety profile of the addition of apremilast to existing therapies including topicals, phototherapy, and systemic agents for the treatment of psoriasis. One database was used for the literature search. Seventeen studies with 617 patients met inclusion criteria and were included. Fifteen studies demonstrated beneficial results with excellent safety and efficacy of apremilast combination therapy (CT). Apremilast has been shown to improve the quality of life and reduce symptom severity in moderate to severe psoriasis. The drug’s simple dosing schedule with mild side effect profile makes it a practical option for patients as combination therapy. J Drugs Dermatol. 2021;20(8):837-843. doi:10.36849/JDD.5845.
银屑病是一种慢性炎症性皮肤疾病，源于细胞因子失调。阿普米司特是一种口服磷酸二酯酶-4 抑制剂，经美国食品药品监督管理局（FDA）批准，用于治疗适合光疗或系统治疗的中重度斑块型银屑病患者。该药物增加环磷酸腺苷（cAMP），调节促炎细胞因子的表达。本综述旨在探讨和分类描述阿普米司特联合现有疗法（包括局部治疗、光疗和系统药物）治疗银屑病的疗效和安全性概况的现有文献。文献检索仅使用了一个数据库。符合纳入标准并被纳入的有 617 名患者的 17 项研究。其中 15 项研究显示出良好的疗效和安全性，表明阿普米司特联合治疗（CT）有益。阿普米司特可改善中重度银屑病患者的生活质量，减轻症状严重程度。该药具有简单的给药方案和轻度的副作用特征，使其成为联合治疗患者的实用选择。J 皮肤病药物杂志。2021；20(8)：837-843。doi:10.36849/JDD.5845.
